News

Ablynx claimed that ALX-0061 binds to the IL-6 receptor (IL-6R). It has a high potency and demonstrated a favourable pharmacodynamic (PD), pharmacokinetic (PK) and safety profile in pre-clinical

Excipients have a key role in the creation of medicines, in order to preserve the efficacy, safety, and stability of active pharmaceutical ingredients (APIs) and ensuring that they

In Phase I development of the virus detection system, which utilizes PositiveID’s licensed Receptors’ CARA (Combinatorial Artificial Receptor Array) platform, PositiveID successfully achieved proof-of-concept. CARA support and complementary

Sun received the recommendations in concurrence with the Sanofi-Aventis’s suit in the US against it, claiming that it is a case of infringement of patent and asking the

The latest pre-clinical candidate is a small molecule that meets all the chemical and biological criteria set by GSK for a potential new medicine. Galapagos developed the candidate

The Metabolism and Pharmacokinetics group at Charles River, has been conducting radiolabelled trials in man for more than 20 years. The facility includes a GMP clean room, licensed

The partnership is expected to allow MTS and Cool Logistics to expand their operations globally, as well as to offer a complete range of products to all clients.

This is the first of multiple trials that Merrimack and Sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121.

The combined business is expected to generate more than $240m of blow molded bottle and injection molded pre-form sales to over 500 customers from 14 manufacturing facilities in